Numerous New Studies and Expert Event from Roche at ASH 2021

More than 90 abstracts feature the incorporation of Roche medicines at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition this year. In a press release from the company, Roche detailed the data of studies on multiple types of blood diseases, including different lymphomas, and shared more details about an event they are hosting.

Roche highlighted a few significant studies involving their pharmaceuticals in their press release. One of those key studies (Abstract LBA-1) is on the safety and efficacy of POLARIX treatment for patients with diffuse large B-cell lymphoma (DLBCL).

The study investigated the comparison of adding Polivy® (polatuzumab vedotin) to MabThera®/Rituxan® (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) and the standard treatment regimen of MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

Notably, results showed improvements in progression-free survival of patients with DLBCL when using Prolivy plus R-CHP. The safety profile with the treatment was similar to R-CHOP for patients. The POLARIX study is being performed in concert with two lymphoma research organizations.

There will also be a Live Media Event at ASH hosted by Roche. The event focuses on improving outcomes for patients with blood disorders through reexamining treatment standards. Experts will be sharing and further explaining critical new data related to Roche’s work being presented at ASH.

Dr. Levi Garraway, the Chief Medical Officer and Head of Global Product Development at Roche, expressed that the company is aiming to fortify their underlying principle “that following the science and developing versatile treatment approaches leads to improved outcomes for patients in increasingly meaningful ways [1].”

Source:

[1] Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders. (2021, November 23). [Press release]. https://www.roche.com/media/releases/med-cor-2021-11-23.htm

Most Recent

Cardiovascular Disease

Cardiovascular Risk Management

Noninvasive Imaging Aids Selection of Stenosis Patients Needing Revascularization Procedure

CT fractional flow reserve analysis safely cuts rates of invasive procedures without compromising safety Computed tomography fractional flow reserve (CT-FFR) improves assessment of vessel blockages and reduces the number of stenosis patients referred for invasive revascularization procedures, according to a study published online April 4 in Radiology: Cardiothoracic Imaging. Mangun K. Randhawa, M.D., from Massachusetts General...

Oncology

Thyroid Cancer

GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer

No increased risk for thyroid cancer seen with use of GLP1 receptor agonist versus DPP4 inhibitor use, SGLT2 inhibitor use Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid cancer, according to a study published online April 10 in The BMJ. Björn Pasternak, M.D., Ph.D., from...

Breast Cancer

OBGYN & Women's Health

Oncology

Mortality Up for Breast Cancer Diagnosed Five to <10 Years After Childbirth

Increased risk for all-cause mortality seen with postpartum young-onset breast cancer in women with germline BRCA pathogenic variants Young-onset breast cancer (YOBC) with germline BRCA pathogenic variants (PVs) is associated with an increased risk for all-cause mortality if diagnosed within 10 years after childbirth, according to a study published online April 19 in JAMA Network Open. Zhenzhen Zhang,...